Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: CD52

Summary for CD52

Gene information	Gene symbol	CD52
	Ensembl ID	ENSG00000169442
	Entrez ID	1043
	Gene name	CD52 molecule
	Synonyms	CDW52\|EDDM5\|HE5
	Gene type	protein_coding
	UniProtAcc	P31358

Top

Dataset with differentially expressed gene: CD52

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.282314	4.68e-14
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.437426	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.373374	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.330231	2.53e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.266458	8.81e-12
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.410469	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.619055	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.449939	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.294929	5.32e-21
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.426065	4.42e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.402852	5.23e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.676736	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.255639	1.90e-05
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.43217	1.86e-09
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.726711	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	-0.484145	9.07e-07
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.372101	3.66e-25
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.290827	2.53e-10
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.793221	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.312038	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.621702	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.623279	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.323844	6.31e-44
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.29313	2.52e-37
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Progenitors	0.90959	2.43e-04
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-1.03606	6.31e-15
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	0.957773	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	Mono/Macro	-0.33513	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	Plasma cells	-0.475887	1.13e-04
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	0.369051	3.17e-16
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.963706	5.82e-30
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.624358	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	0.618609	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.410328	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.531366	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.729019	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.59002	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.512268	2.80e-45
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.311567	2.27e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	-0.57523	4.40e-24
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.480798	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.630642	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	-0.592572	1.85e-11
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD8+ T cells	-0.286424	2.45e-03
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	cDCs	-0.634275	1.71e-02
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.480827	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.941862	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	2.17209	5.54e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.6331	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.438527	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	1.79886	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	1.18758	6.70e-40
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.390687	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-2.25601	2.64e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	0.581771	1.21e-43
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	0.503459	1.59e-07
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	0.787669	3.08e-44
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	-0.67394	1.90e-35
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	0.52136	2.33e-20
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.685816	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.382721	1.22e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.464773	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.410094	1.99e-36
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.408855	1.10e-19
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.260177	2.14e-16

Top

Expression of CD52 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CD52

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	Malignant cells	Mono/Macro	GSE111014	pre	resistant
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE111014	pre	resistant
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Malignant cells	GSE111014	pre	sensitive
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	Malignant cells	Mono/Macro	GSE111014	pre	sensitive
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Malignant cells	GSE111014	pre	sensitive
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE111014	pre	sensitive
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	Malignant cells	Mono/Macro	GSE150930	NA	resistant
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	Malignant cells	Mono/Macro	GSE153697	NA	resistant
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	Malignant cells	Mono/Macro	GSE153697	NA	sensitive
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	Mono/Macro	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	NK cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	cDCs	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	NK cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	NK cells	Mono/Macro	GSE161801_IMiD	pre	resistant
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	B cells	GSE162117	post	resistant
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Malignant cells	GSE162117	pre	sensitive
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Malignant cells	GSE162117	pre	sensitive
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Malignant cells	GSE162117	pre	sensitive
CD52	Malignant cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	NK cells	Malignant cells	GSE162117	pre	sensitive
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Malignant cells	GSE162117	pre	sensitive
CD52	CD4+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE164551	NA	sensitive
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE169246_PacAteBlood	post	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	post	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteBlood	post	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE169246_PacAteBlood	post	sensitive
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	post	sensitive
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteBlood	post	sensitive
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE169246_PacAteBlood	pre	sensitive
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	sensitive
CD52	Mono/Macro	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	sensitive
CD52	CD4+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	B cells	GSE169246_PacAteTissue	post	resistant
CD52	CD4+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mast cells	GSE169246_PacAteTissue	post	resistant
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	B cells	GSE169246_PacAteTissue	post	resistant
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mast cells	GSE169246_PacAteTissue	post	resistant
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	B cells	GSE169246_PacAteTissue	post	resistant
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	B cells	GSE169246_PacAteTissue	post	resistant
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	NK cells	B cells	GSE169246_PacAteTissue	post	resistant
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	B cells	GSE169246_PacAteTissue	post	resistant
CD52	CD8+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD8+ T cells	Mast cells	GSE169246_PacAteTissue	post	resistant
CD52	CD4+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	B cells	GSE169246_PacAteTissue	post	sensitive
CD52	CD4+ T cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	B cells	GSE169246_PacAteTissue	post	sensitive
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	B cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
CD52	B cells	CPI-SS073C1B796	CD52_SIGLEC10	CD52	SIGLEC10	False	CD4+ T cells	B cells	GSE169246_PacAteTissue	post	sensitive

Page: 1 2 3 4

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating CD52

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CD52	hsa-miR-186-3p	85.6766	NM_001803

Page: 1

Top

Motifs and transcription factors (TFs) regulating CD52

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CD52	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
CD52	transfac_pro__M05916	ZNF407 (directAnnotation).
CD52	transfac_pro__M06404	ZNF497 (directAnnotation).
CD52	swissregulon__hs__HBP1	HBP1 (directAnnotation).
CD52	transfac_pro__M06557	ZNF418 (directAnnotation).
CD52	metacluster_111.5	E4F1; E4F1 (directAnnotation).
CD52	metacluster_27.14	ZFP1; ZFP1 (directAnnotation).
CD52	transfac_pro__M06130	ZNF254 (directAnnotation).
CD52	hocomoco__HSF1_MOUSE.H11MO.1.A	HSF1 (inferredBy_Orthology).
CD52	metacluster_145.10	ZNF24 (directAnnotation).
CD52	transfac_pro__M06486	ZNF610 (directAnnotation).
CD52	transfac_pro__M06751	ZNF510 (directAnnotation).
CD52	jaspar__MA1956.1	FOXO1 (directAnnotation).
CD52	metacluster_159.8	ZNF770 (directAnnotation). ZNF770 (inferredBy_Orthology).
CD52	tfdimers__MD00463	CHURC1; DBP (directAnnotation).
CD52	metacluster_165.8	HBP1 (directAnnotation). HBP1 (inferredBy_Orthology).
CD52	metacluster_56.3	HSF2 (directAnnotation).
CD52	transfac_pro__M06272	ZNF569 (directAnnotation).
CD52	kznf__ZNF3_Imbeault2017_RP_RCADE	ZNF3 (directAnnotation).
CD52	transfac_pro__M06549	ZNF721 (directAnnotation).
CD52	metacluster_155.21	ZNF454; ZNF454 (directAnnotation).
CD52	kznf__ZNF45_Imbeault2017_OM_RCADE	ZNF45 (directAnnotation).
CD52	metacluster_130.12	ZNF182; ZNF35; ZNF674; ZNF677; ZNF79; ZNF836 (directAnnotation).
CD52	transfac_pro__M06426	ZNF761 (directAnnotation).
CD52	jaspar__MA1125.1	ZNF384 (directAnnotation).
CD52	taipale_tf_pairs__HOXB13_ELK1_RSMGGAARTNNTAAAN_CAP	ELK1; HOXB13 (directAnnotation).
CD52	transfac_pro__M06470	ZNF441 (directAnnotation).
CD52	taipale_tf_pairs__HOXB13_ETV1_RSCGGAARYNNTAAAN_CAP_repr	ETV1; HOXB13 (directAnnotation).
CD52	taipale_tf_pairs__ETV2_GSC2_RSCGGAANNNNGGATTA_CAP_repr	ETV2; GSC2 (directAnnotation).
CD52	taipale_tf_pairs__HOXD12_ETV4_RSCGGAAGTAATAAAN_CAP	ETV4; HOXD12 (directAnnotation).
CD52	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
CD52	transfac_pro__M05788	ZNF569 (inferredBy_Orthology).
CD52	transfac_pro__M06023	ZSCAN32 (directAnnotation).
CD52	transfac_pro__M05984	ZNF586 (directAnnotation).
CD52	metacluster_131.3	ZNF436 (inferredBy_Orthology).
CD52	tfdimers__MD00367	CDX2; IKZF1 (directAnnotation).
CD52	jaspar__MA0684.2	RUNX3 (directAnnotation).
CD52	transfac_pro__M06462	ZNF441 (directAnnotation).
CD52	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
CD52	taipale_tf_pairs__TEAD4_ELK1_RGAATSCGGAAGYN_CAP	ELK1; TEAD4 (directAnnotation).
CD52	transfac_pro__M06334	ZNF782 (directAnnotation).
CD52	transfac_pro__M06506	ZFP62 (directAnnotation).
CD52	jaspar__MA1933.1	SREBF2 (directAnnotation).
CD52	transfac_pro__M06173	ZNF85 (directAnnotation).
CD52	metacluster_79.1	ZNF713; ZNF713; ZNF713 (directAnnotation).
CD52	transfac_pro__M05711	ZNF37A (directAnnotation).
CD52	cisbp__M00146	ZBTB12 (inferredBy_Orthology).
CD52	metacluster_21.2	ZBTB12; ZBTB26; ZBTB26 (directAnnotation).
CD52	kznf__ZNF124_Imbeault2017_OM_RCADE	ZNF124 (directAnnotation).
CD52	metacluster_155.31	ZNF131 (directAnnotation). ZNF131 (inferredBy_Orthology).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
CD52	"Alemtuzumab"	DB00087	biotech

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."